Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Biogen

Next Previous
Drug Profile

Interferon beta-1a - Biogen

Alternative Names: Avonex; Avonex Pen; IFN-b-1a; Interferon β-1a

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Eisai Co Ltd; Merck & Co; Nektar Therapeutics
  • Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 01 Apr 2021 No development reported - Phase-II for Multiple sclerosis (Adjunctive treatment) in Italy (SC) (Biogen pipeline, April 2021)
  • 06 Feb 2020 Merck KGaA terminates the phase II INCREASE trial in Multiple sclerosis (Adjunctive treatment) in Italy due to slow recruitment (SC) (NCT03387046)
  • 11 Jan 2019 Merck KGaA completes the phase-II INCREASE trial in Multiple sclerosis in Italy (NCT03387046)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top